Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.
A mutant protein called Siglec-XII may promote carcinoma progression in humans, but inactivation of its gene seems to avoid the problem, according to a study.